In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Fate Therapeutics Inc’s stock clocked out at $1.15, down -0.86% from its previous closing price of $1.16. In other words, the price has decreased by -$0.86 from its previous closing price. On the day, 1.02 million shares were traded. FATE stock price reached its highest trading level at $1.17 during the session, while it also had its lowest trading level at $1.12.
Ratios:
To gain a deeper understanding of FATE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 131827944 and an Enterprise Value of -28704016. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.88 while its Price-to-Book (P/B) ratio in mrq is 0.46. Its current Enterprise Value per Revenue stands at -2.153 whereas that against EBITDA is 0.171.
Stock Price History:
The Beta on a monthly basis for FATE is 2.25, which has changed by -0.70437014 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $5.92, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -4.41%, while the 200-Day Moving Average is calculated to be -31.74%.
Shares Statistics:
It appears that FATE traded 1.99M shares on average per day over the past three months and 1742960 shares per day over the past ten days. A total of 114.60M shares are outstanding, with a floating share count of 107.09M. Insiders hold about 6.58% of the company’s shares, while institutions hold 84.03% stake in the company. Shares short for FATE as of 1749772800 were 9512319 with a Short Ratio of 4.80, compared to 1747267200 on 12870954. Therefore, it implies a Short% of Shares Outstanding of 9512319 and a Short% of Float of 9.4799995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 10.0 analysts currently analyzing and rating the stock of Fate Therapeutics Inc (FATE).The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.23 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.0 and -$1.38 for the fiscal current year, implying an average EPS of -$1.24. EPS for the following year is -$1.15, with 10.0 analysts recommending between -$0.73 and -$1.53.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $13.6M, while the lowest revenue estimate was $1.63M, resulting in an average revenue estimate of $5.33M. In the same quarter a year ago, actual revenue was $13.63M
